What is the main reason for this 8-K filing?

This 8-K filing is primarily to inform investors about the U.S. Department of Justice's decision to file a civil antitrust lawsuit to block Anthem, Inc.'s proposed acquisition of Cigna Corporation and to communicate Anthem's immediate response.

What is Anthem's stance on the DOJ's lawsuit?

Anthem, Inc. stated that it is fully committed to challenging the DOJ's decision in court. However, the company also indicated that it remains open to discussions to reach a settlement with the DOJ that would allow the acquisition to proceed.

What are the potential implications for investors?

The DOJ's lawsuit represents a significant obstacle to the proposed merger, creating uncertainty for investors regarding the completion of the transaction. The outcome of the legal challenge and any potential settlement will critically impact the future strategic direction and financial performance of Elevance Health.

Where can investors find more information about the acquisition and related legal matters?

Investors are urged to refer to Anthem's and Cigna's filings with the SEC, including the Form S-4 registration statement and joint proxy statement/prospectus, which contain important information about the proposed transaction. The company also provided contact information for Investor Relations in the filing.

ELV 8-K SEC Disclosure — Jul 21, 2016

Summary

Elevance Health, Inc. (formerly Anthem, Inc.) filed an 8-K on July 21, 2016, to report on a significant development regarding its proposed acquisition of Cigna Corporation. The U.S. Department of Justice (DOJ) had filed a civil antitrust lawsuit on July 20, 2016, seeking to block the merger. In response, Elevance Health announced its full commitment to challenging the DOJ's decision in court. However, the company also indicated openness to settlement discussions with the DOJ in hopes of still completing the acquisition. This filing signals a critical legal hurdle for the proposed transaction and highlights the intense regulatory scrutiny it faced. Investors should monitor legal proceedings and potential settlement outcomes closely, as they will directly impact the future structure and scale of the company.

Key Highlights

1The U.S. Department of Justice (DOJ) filed a civil antitrust lawsuit to block the acquisition of Cigna Corporation by Anthem, Inc. (now Elevance Health).
2Anthem, Inc. issued a press release on July 21, 2016, addressing the DOJ's lawsuit.
3The company stated its full commitment to challenging the DOJ's decision in court.
4Anthem expressed receptiveness to settlement efforts with the DOJ to facilitate the completion of the Cigna acquisition.
5The filing includes Exhibit 99.1, which is the press release detailing the company's response to the DOJ's lawsuit.
6The report clarifies that information furnished in Item 8.01 and Exhibit 99.1 is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings.

Elevance Health, Inc. 8-K Report, Corporate Update (Jul 21, 2016)

Summary

Key Highlights

Frequently Asked Questions